Gerrit R. J. Melles
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Gerrit R. J. Melles has a total of 57 co-authors. Here are the top co-authors by number of shared publications:
Lisanne Ham
Netherlands Institute for Innovative Ocular Surgery, Rotterdam, the Netherlands2Melles Cornea Clinic Rotterdam, Rotterdam, the Netherlands4Amnitrans EyeBank Rotterdam, Rotterdam, the Netherlands
5 shared publicationsKorine van Dijk
Netherlands Institute for Innovative Ocular Surgery, Rotterdam, the Netherlands2Melles Cornea Clinic Rotterdam, Rotterdam, the Netherlands
4 shared publicationsIsabel Dapena
Netherlands Institute for Innovative Ocular Surgery, Rotterdam, the Netherlands
3 shared publicationsJack Parker
Netherlands Institute for Innovative Ocular Surgery, Rotterdam, the Netherlands2Melles Cornea Clinic Rotterdam, Rotterdam, the Netherlands3UAB Callahan Eye Hospital, Birmingham, Alabama
3 shared publicationsJessica T. Lie
Netherlands Institute for Innovative Ocular Surgery, Rotterdam, the Netherlands4Amnitrans EyeBank Rotterdam, Rotterdam, the Netherlands
3 shared publicationsMarieke Bruinsma
Netherlands Institute for Innovative Ocular Surgery (NIIOS), Rotterdam, The Netherlands
3 shared publications
Latest Publications
- 26 April 2014
- Published by Springer Nature in Der Ophthalmologe
- Vol. 111 (11) , 1041-1049
Standardisierte Descemet-Membran-Endothelkeratoplastik (DMEK)
Zur Behandlung endothelialer Hornhauterkrankungen haben sich die Verfahren der posterioren lamellären Keratoplastiken inzwischen als Therapie der Wahl durchgesetzt. Die „Descemet membrane endothelial keratoplasty“ (DMEK) stellt das jüngste Verfahren dar. Mit dieser Studie wurden 400 konsekutive Fälle nach der standardisierten No-touch-DMEK evaluiert. Es handelt sich um eine nicht randomisierte, retrospektive klinische Studie. Von 400 konsekutiven DMEK-Augen (321 Patienten) wurden der bestkorrigierte Visus, die Endothelzelldichte (EZD) und Hornhautpachymetrie sowie Komplikationen innerhalb der ersten 6 Monate nach DMEK evaluiert. Zusätzlich wurden 2 Subgruppen (I: Fälle 1 bis 200; II: Fälle 201 bis 400) getrennt voneinander ausgewertet. Nach 6 Monaten erreichten 80 % aller Augen einen bestkorrigierten Visus von ≥ 0,8, 44 % von ≥ 1,0 und 14 % von ≥ 1,2. Zwischen den Subgruppen bestand kein signifikanter Unterschied. Die Endothelzelldichte nahm durchschnittlich von präoperativ 2542 (± 217) Zellen/mm2 auf 1622 (± 500) Zellen/mm2 nach 6 Monaten ab (− 36 %). Die Anzahl der Folgeeingriffe lag bei 5 %, wobei drei Viertel davon in der ersten Subgruppe durchgeführt wurden. Die nun standardisierte No-touch-DMEK-Technik ermöglicht bei der Mehrzahl der operierten Augen eine rasche und fast vollständige Visusrehabilitation. Sie ist eine sichere Operationsmethode, die sich zum Standardverfahren der posterioren lamellären Keratoplastiken entwickelt. The procedure of posterior lamellar keratoplasty has now become established as first choice therapy for the treatment of corneal endothelial diseases, with Descemet membrane endothelial keratoplasty (DMEK) as the most recent refinement of endothelial keratoplasty techniques. In this study the outcome of 400 consecutive cases after standardized no-touch DMEK was evaluated. This was a non-randomized retrospective clinical study of 400 consecutive eyes in 321 patients who underwent standard DMEK. Outcome measures included best corrected visual acuity (BCVA) preoperatively and postoperatively at 1, 3 and 6 months, endothelial cell density (ECD), pachymetry and complications within the first 6 months. In addition two subgroups were analyzed (subgroup I cases 1–200 and subgroup II cases 201–400). At 6 months postoperatively 80 % of all eyes had a BCVA of ≥ 20/25 (≥ 0.8), 44 % of ≥ 20/20 (≥ 1.0) and 14 % of ≥ 20/18 (≥ 1.2). There were no significant differences between the two subgroups. The mean ECD preoperatively was 2,542 (± 217) cells/mm2 and 6 months postoperatively 1,622 (± 500) cells/mm2. The mean ECD decrease was 36 % 6 months after DMEK. No difference between the subgroups was noted. In 5 % a re-operation was needed of which 75 % were performed in subgroup I. With the standardized no-touch DMEK technique a rapid and nearly complete visual rehabilitation as well as ECD values similar to earlier endothelial keratoplasty techniques can be achieved. Therefore DMEK may become the preferred treatment for corneal endothelial disorders.
- 26 April 2014
- Published by Springer Nature in Der Ophthalmologe
- Vol. 111 (11) , 1041-1049
Standardisierte Descemet-Membran-Endothelkeratoplastik (DMEK)
Zur Behandlung endothelialer Hornhauterkrankungen haben sich die Verfahren der posterioren lamellären Keratoplastiken inzwischen als Therapie der Wahl durchgesetzt. Die „Descemet membrane endothelial keratoplasty“ (DMEK) stellt das jüngste Verfahren dar. Mit dieser Studie wurden 400 konsekutive Fälle nach der standardisierten No-touch-DMEK evaluiert. Es handelt sich um eine nicht randomisierte, retrospektive klinische Studie. Von 400 konsekutiven DMEK-Augen (321 Patienten) wurden der bestkorrigierte Visus, die Endothelzelldichte (EZD) und Hornhautpachymetrie sowie Komplikationen innerhalb der ersten 6 Monate nach DMEK evaluiert. Zusätzlich wurden 2 Subgruppen (I: Fälle 1 bis 200; II: Fälle 201 bis 400) getrennt voneinander ausgewertet. Nach 6 Monaten erreichten 80 % aller Augen einen bestkorrigierten Visus von ≥ 0,8, 44 % von ≥ 1,0 und 14 % von ≥ 1,2. Zwischen den Subgruppen bestand kein signifikanter Unterschied. Die Endothelzelldichte nahm durchschnittlich von präoperativ 2542 (± 217) Zellen/mm2 auf 1622 (± 500) Zellen/mm2 nach 6 Monaten ab (− 36 %). Die Anzahl der Folgeeingriffe lag bei 5 %, wobei drei Viertel davon in der ersten Subgruppe durchgeführt wurden. Die nun standardisierte No-touch-DMEK-Technik ermöglicht bei der Mehrzahl der operierten Augen eine rasche und fast vollständige Visusrehabilitation. Sie ist eine sichere Operationsmethode, die sich zum Standardverfahren der posterioren lamellären Keratoplastiken entwickelt. The procedure of posterior lamellar keratoplasty has now become established as first choice therapy for the treatment of corneal endothelial diseases, with Descemet membrane endothelial keratoplasty (DMEK) as the most recent refinement of endothelial keratoplasty techniques. In this study the outcome of 400 consecutive cases after standardized no-touch DMEK was evaluated. This was a non-randomized retrospective clinical study of 400 consecutive eyes in 321 patients who underwent standard DMEK. Outcome measures included best corrected visual acuity (BCVA) preoperatively and postoperatively at 1, 3 and 6 months, endothelial cell density (ECD), pachymetry and complications within the first 6 months. In addition two subgroups were analyzed (subgroup I cases 1–200 and subgroup II cases 201–400). At 6 months postoperatively 80 % of all eyes had a BCVA of ≥ 20/25 (≥ 0.8), 44 % of ≥ 20/20 (≥ 1.0) and 14 % of ≥ 20/18 (≥ 1.2). There were no significant differences between the two subgroups. The mean ECD preoperatively was 2,542 (± 217) cells/mm2 and 6 months postoperatively 1,622 (± 500) cells/mm2. The mean ECD decrease was 36 % 6 months after DMEK. No difference between the subgroups was noted. In 5 % a re-operation was needed of which 75 % were performed in subgroup I. With the standardized no-touch DMEK technique a rapid and nearly complete visual rehabilitation as well as ECD values similar to earlier endothelial keratoplasty techniques can be achieved. Therefore DMEK may become the preferred treatment for corneal endothelial disorders.
- Open Access
- 1 April 2014
- Published by American Medical Association (AMA) in JAMA Ophthalmology
- Vol. 132 (4) , 495-501
Midstromal Isolated Bowman Layer Graft for Reduction of Advanced Keratoconus
Midstromal implant of an isolated Bowman layer graft is a new approach to reduce ectasia in eyes with advanced keratoconus. The procedure should postpone penetrating or deep anterior lamellar keratoplasty. Ten eyes of 9 patients with progressive, advanced keratoconus and contact lens intolerance underwent the procedure with no intraoperative adverse events. Throughout the study period, we observed no complications related to stromal dissection and/or the Bowman layer graft. Maximum corneal power decreased from a mean (SD) of 74.5 (7.1) diopters (D) before to 68.3 (5.6) D after surgery (P = .002). Hence, implant of an isolated Bowman layer graft may offer a safe and effective new technique to reduce ectasia in eyes with advanced keratoconus, potentially allowing continued long-term contact lens wear. The low risk of complications may render the procedure suitable as a treatment to postpone penetrating or deep anterior lamellar keratoplasty in cases with impending contact lens intolerance and/or corneal scarring (clinicaltrials.gov Identifier: NCT01686906).
- 1 April 2014
- Published by American Medical Association (AMA) in JAMA Ophthalmology
- Vol. 132 (4) , 495-501
Open AccessMidstromal Isolated Bowman Layer Graft for Reduction of Advanced Keratoconus
Midstromal implant of an isolated Bowman layer graft is a new approach to reduce ectasia in eyes with advanced keratoconus. The procedure should postpone penetrating or deep anterior lamellar keratoplasty. Ten eyes of 9 patients with progressive, advanced keratoconus and contact lens intolerance underwent the procedure with no intraoperative adverse events. Throughout the study period, we observed no complications related to stromal dissection and/or the Bowman layer graft. Maximum corneal power decreased from a mean (SD) of 74.5 (7.1) diopters (D) before to 68.3 (5.6) D after surgery (P = .002). Hence, implant of an isolated Bowman layer graft may offer a safe and effective new technique to reduce ectasia in eyes with advanced keratoconus, potentially allowing continued long-term contact lens wear. The low risk of complications may render the procedure suitable as a treatment to postpone penetrating or deep anterior lamellar keratoplasty in cases with impending contact lens intolerance and/or corneal scarring (clinicaltrials.gov Identifier: NCT01686906).
- 21 February 2014
- Published by Springer Nature in Eye
- Vol. 28 (5) , 636
Reply to Fuchs fuchs Fuch’s and Fuchs’!
- 21 February 2014
- Published by Springer Nature in Eye
- Vol. 28 (5) , 636
Reply to Fuchs fuchs Fuch’s and Fuchs’!
- 12 July 2013
- Published by Springer Nature in Eye
- Vol. 27 (10) , 1115-1122
What does the future hold for the treatment of Fuchs endothelial dystrophy; will ‘keratoplasty’ still be a valid procedure?
Fuchs endothelial corneal dystrophy (FECD) is a well recognized corneal disorder characterized by the presence of collagenous warts extending from Descemet membrane (guttae) and endothelial cellular dysfunction due to cell loss and/or degeneration. Because of the characteristic abnormal cell morphology as seen with specular microscopy as well as the limited regenerative capacity in vivo, the endothelial cells were considered to be 'dystrophic'. Hence, FECD is commonly managed by replacement of the endothelium with donor tissue by means of a penetrating or endothelial keratoplasty. The latter procedure has now been refined to the isolated transplantation of a donor Descemet membrane and its endothelium, referred to as Descemet membrane endothelial keratoplasty (DMEK). Unexpectedly, clinical observation made after DMEK seemed to challenge the current concept of the state of the endothelium in FECD; we actually observed an important role for the 'dystrophic' host endothelium in re-endothelialization of the denuded DM, and subsequent corneal clearance. In addition, recent studies regarding the pathophysiology of FECD made us realize that the endothelial cells are not 'dystrophic' per se, but in the course of time may have acquired a dysfunction instead. This paper describes the rationale behind this new concept and based on this, discusses the possibilities for future, less invasive treatment modalities for FECD.
- 12 July 2013
- Published by Springer Nature in Eye
- Vol. 27 (10) , 1115-1122
What does the future hold for the treatment of Fuchs endothelial dystrophy; will ‘keratoplasty’ still be a valid procedure?
Fuchs endothelial corneal dystrophy (FECD) is a well recognized corneal disorder characterized by the presence of collagenous warts extending from Descemet membrane (guttae) and endothelial cellular dysfunction due to cell loss and/or degeneration. Because of the characteristic abnormal cell morphology as seen with specular microscopy as well as the limited regenerative capacity in vivo, the endothelial cells were considered to be 'dystrophic'. Hence, FECD is commonly managed by replacement of the endothelium with donor tissue by means of a penetrating or endothelial keratoplasty. The latter procedure has now been refined to the isolated transplantation of a donor Descemet membrane and its endothelium, referred to as Descemet membrane endothelial keratoplasty (DMEK). Unexpectedly, clinical observation made after DMEK seemed to challenge the current concept of the state of the endothelium in FECD; we actually observed an important role for the 'dystrophic' host endothelium in re-endothelialization of the denuded DM, and subsequent corneal clearance. In addition, recent studies regarding the pathophysiology of FECD made us realize that the endothelial cells are not 'dystrophic' per se, but in the course of time may have acquired a dysfunction instead. This paper describes the rationale behind this new concept and based on this, discusses the possibilities for future, less invasive treatment modalities for FECD.
- 20 June 2013
- Published by Wiley in Acta Ophthalmologica
- Vol. 92 (4) , 339-344
Novel ‘heavy’ dyes for retinal membrane staining during macular surgery: multicenter clinical assessment
To evaluate the feasibility of two novel 'heavy' dye solutions for staining the internal limiting membrane (ILM) and epiretinal membranes (ERMs), without the need for a prior fluid-air exchange, during macular surgery. In this prospective nonrandomized multicenter cohort study, the high molecular weight dyes ILM-Blue™ [0.025% brilliant blue G, 4% polyethylene glycol (PEG)] and MembraneBlue-Dual™ (0.15% trypan blue, 0.025% brilliant blue G, 4% PEG) were randomly used in vitrectomy surgeries for macular disease in 127 eyes of 127 patients. Dye enhanced membrane visualization of the ILM and ERMs, 'ease of membrane peeling', visually detectable perioperative retinal damage, postoperative best-corrected visual acuity (BCVA), dye remnants and other unexpected clinical events were documented by 21 surgeons. All surgeries were uneventful, and a clear bluish staining, facilitating the identification, delineation and removal of the ILM and ERMs, was reported in all but five cases. None of the surgeries required a fluid-air exchange to assist the dye application. BCVA at 1 month after surgery improved in 83% of the eyes in the MembraneBlue-Dual™ group and in 88% in the ILM-Blue™ group. No dye remnants were detected by ophthalmoscopy, and no retinal adverse effects related to the surgery or use of the dyes were observed. The 'heavy' dye solutions ILM-Blue™ and MembraneBlue-Dual™ can be injected into a fluid-filled vitreous cavity and may facilitate staining and removal of the ILM and/or ERMs in macular surgery without an additional fluid-air exchange.
- 20 June 2013
- Published by Wiley in Acta Ophthalmologica
- Vol. 92 (4) , 339-344
Novel ‘heavy’ dyes for retinal membrane staining during macular surgery: multicenter clinical assessment
To evaluate the feasibility of two novel 'heavy' dye solutions for staining the internal limiting membrane (ILM) and epiretinal membranes (ERMs), without the need for a prior fluid-air exchange, during macular surgery. In this prospective nonrandomized multicenter cohort study, the high molecular weight dyes ILM-Blue™ [0.025% brilliant blue G, 4% polyethylene glycol (PEG)] and MembraneBlue-Dual™ (0.15% trypan blue, 0.025% brilliant blue G, 4% PEG) were randomly used in vitrectomy surgeries for macular disease in 127 eyes of 127 patients. Dye enhanced membrane visualization of the ILM and ERMs, 'ease of membrane peeling', visually detectable perioperative retinal damage, postoperative best-corrected visual acuity (BCVA), dye remnants and other unexpected clinical events were documented by 21 surgeons. All surgeries were uneventful, and a clear bluish staining, facilitating the identification, delineation and removal of the ILM and ERMs, was reported in all but five cases. None of the surgeries required a fluid-air exchange to assist the dye application. BCVA at 1 month after surgery improved in 83% of the eyes in the MembraneBlue-Dual™ group and in 88% in the ILM-Blue™ group. No dye remnants were detected by ophthalmoscopy, and no retinal adverse effects related to the surgery or use of the dyes were observed. The 'heavy' dye solutions ILM-Blue™ and MembraneBlue-Dual™ can be injected into a fluid-filled vitreous cavity and may facilitate staining and removal of the ILM and/or ERMs in macular surgery without an additional fluid-air exchange.
- 1 May 2013
- Published by Wolters Kluwer Health in Cornea
- Vol. 32 (5) , e74-e78
Large Diameter Descemet Membrane Endothelial Keratoplasty in Buphthalmic Eyes
Purpose: To report the outcomes of Descemet membrane endothelial keratoplasty (DMEK) using a large diameter graft in the management of endothelial decompensation in buphthalmic eyes. Methods: Four eyes of 4 adults (1 man, 3 women) with bullous keratopathy and buphthalmos secondary to congenital glaucoma were treated with DMEK using posterior lamellar grafts with diameters ranging from 10 to 12 mm. The mean age was 31 (±9) years (range, 20–38 years). Mean follow-up time was 13.5 (±7.5) months (range, 6–24 months). Main outcome measures were best-corrected visual acuity (BCVA), intraocular pressure (IOP), pachymetry, endothelial cell density, and complications after surgery. Results: In all eyes, there was improved corneal clarity with decrease in pachymetry. The final postoperative BCVA improved in most eyes. There was no significant change in IOP, with 3 eyes needing additional antiglaucoma medication. Endothelial cell loss ranged from 37% to 42%. Postoperative complications were early partial graft detachment in 2 eyes, one resolving spontaneously without intervention and the other requiring a rebubbling, and cataract formation requiring phacoemulsification in 1 eye. Conclusions: DMEK using a large or even full diameter Descemet membrane graft may be an effective treatment for bullous keratopathy in buphthalmic eyes. Partial graft detachment after surgery may be the main complication. Postoperative IOP control is mandatory, and BCVA may vary with ocular comorbidity unrelated to the transplanted cornea.
- 1 May 2013
- Published by Wolters Kluwer Health in Cornea
- Vol. 32 (5) , e74-e78
Large Diameter Descemet Membrane Endothelial Keratoplasty in Buphthalmic Eyes
Purpose: To report the outcomes of Descemet membrane endothelial keratoplasty (DMEK) using a large diameter graft in the management of endothelial decompensation in buphthalmic eyes. Methods: Four eyes of 4 adults (1 man, 3 women) with bullous keratopathy and buphthalmos secondary to congenital glaucoma were treated with DMEK using posterior lamellar grafts with diameters ranging from 10 to 12 mm. The mean age was 31 (±9) years (range, 20–38 years). Mean follow-up time was 13.5 (±7.5) months (range, 6–24 months). Main outcome measures were best-corrected visual acuity (BCVA), intraocular pressure (IOP), pachymetry, endothelial cell density, and complications after surgery. Results: In all eyes, there was improved corneal clarity with decrease in pachymetry. The final postoperative BCVA improved in most eyes. There was no significant change in IOP, with 3 eyes needing additional antiglaucoma medication. Endothelial cell loss ranged from 37% to 42%. Postoperative complications were early partial graft detachment in 2 eyes, one resolving spontaneously without intervention and the other requiring a rebubbling, and cataract formation requiring phacoemulsification in 1 eye. Conclusions: DMEK using a large or even full diameter Descemet membrane graft may be an effective treatment for bullous keratopathy in buphthalmic eyes. Partial graft detachment after surgery may be the main complication. Postoperative IOP control is mandatory, and BCVA may vary with ocular comorbidity unrelated to the transplanted cornea.
- 1 January 2013
- Published by Touch Medical Media, Ltd. in US Ophthalmic Review
- Vol. 06 (01)
Descemet Membrane Endothelial Keratoplasty—A Review
Descemet membrane endothelial keratoplasty (DMEK) is the most recent step forward in the evolution of endothelial keratoplasty toward thinner grafts and more natural, anatomic corneal restoration. Offering unprecedented visual results and requiring no special or expensive equipment, DMEK has the potential to become the first line treatment for corneal endothelial disorders. The surgery’s perceived shortcomings (primarily technical difficulty) have mostly been addressed by new ‘no-touch’ procedures for both graft preparation and graft unfolding in the recipient eye. And as a result, DMEK has been gaining traction with ophthalmologists the world over. Now, in its most recent formulation, DMEK is ready for the typical corneal surgeon, in any clinical setting, and at low cost.
- 1 January 2013
- Published by Touch Medical Media, Ltd. in US Ophthalmic Review
- Vol. 06 (01)
Descemet Membrane Endothelial Keratoplasty—A Review
Descemet membrane endothelial keratoplasty (DMEK) is the most recent step forward in the evolution of endothelial keratoplasty toward thinner grafts and more natural, anatomic corneal restoration. Offering unprecedented visual results and requiring no special or expensive equipment, DMEK has the potential to become the first line treatment for corneal endothelial disorders. The surgery’s perceived shortcomings (primarily technical difficulty) have mostly been addressed by new ‘no-touch’ procedures for both graft preparation and graft unfolding in the recipient eye. And as a result, DMEK has been gaining traction with ophthalmologists the world over. Now, in its most recent formulation, DMEK is ready for the typical corneal surgeon, in any clinical setting, and at low cost.
- Open Access
- 1 January 2013
- Published by American Medical Association (AMA) in JAMA Ophthalmology
- Vol. 131 (1) , 29-35
Intraocular Graft Unfolding Techniques in Descemet Membrane Endothelial Keratoplasty
Recently, we described a technique for selective replacement of the Descemet membrane (DM), referred to as DM endothelial keratoplasty (EK), for the management of corneal endothelial disorders.1,2 Although visual outcomes after DMEK may surpass those of earlier endothelial keratoplasty techniques such as Descemet-stripping (automated) endothelial keratoplasty (DSEK/DSAEK),3-5 concerns have been raised about the feasibility of DMEK, in particular unfolding the Descemet graft within the anterior chamber of the recipient eye.6 For that reason, we standardized the procedure as a no-touch surgical technique7 to enable corneal surgeons to begin DMEK with a relatively short learning curve.3,8
- 1 January 2013
- Published by American Medical Association (AMA) in JAMA Ophthalmology
- Vol. 131 (1) , 29-35
Open AccessIntraocular Graft Unfolding Techniques in Descemet Membrane Endothelial Keratoplasty
Recently, we described a technique for selective replacement of the Descemet membrane (DM), referred to as DM endothelial keratoplasty (EK), for the management of corneal endothelial disorders.1,2 Although visual outcomes after DMEK may surpass those of earlier endothelial keratoplasty techniques such as Descemet-stripping (automated) endothelial keratoplasty (DSEK/DSAEK),3-5 concerns have been raised about the feasibility of DMEK, in particular unfolding the Descemet graft within the anterior chamber of the recipient eye.6 For that reason, we standardized the procedure as a no-touch surgical technique7 to enable corneal surgeons to begin DMEK with a relatively short learning curve.3,8
- Open Access
- 19 September 2012
- Published by Wiley in Acta Ophthalmologica
- Vol. 91 (2) , 131-139
Identifying causes for poor visual outcome after DSEK/DSAEK following secondary DMEK in the same eye
: Purpose: To identify causes of reduced visual acuity after Descemet stripping (automated) endothelial keratoplasty (DSEK/DSAEK) and to determine whether such eyes can be successfully ‘repaired’ with a secondary Descemet membrane endothelial keratoplasty (DMEK).Methods: Twelve eyes of 12 patients, who underwent secondary DMEK to manage poor visual outcome after initial DSEK/DSAEK, were evaluated with biomicroscopy, Pentacam imaging, and specular and confocal microscopy, before and at 1, 3 and 6 months after DMEK.Results: Four causes of reduced optical quality of the transplanted host cornea could be identified in DSEK/DSAEK: five eyes (42%) showed large host‐Descemet remnants within the visual axis during surgery; six eyes (50%) irregular graft thickness; six eyes subtle ‘stromal waves’; and nine eyes (75%) high reflectivity at the donor‐to‐host interface. After DMEK graft replacement, all corneas cleared and achieved a best corrected visual acuity of ≥20/25 (≥0.8), except for one with a partial Descemet graft detachment. Pachymetry values decreased from 670 (±112) μm before to 517 (±57) μm after secondary DMEK. Higher‐order aberrations (Coma and Trefoil) at the posterior surface tended to be lower (p = 0.07) in DMEK grafts than in DSEK/DSAEK grafts.Conclusion: Host‐Descemet remnants at the donor‐to‐host interface, interface reflectivity, graft thickness irregularity and donor stromal contraction may contribute to poor visual outcome after DSEK/DSAEK, without causing permanent host corneal damage, as in most cases, complete visual recovery could be achieved by performing a secondary DMEK.
- 19 September 2012
- Published by Wiley in Acta Ophthalmologica
- Vol. 91 (2) , 131-139
Open AccessIdentifying causes for poor visual outcome after DSEK/DSAEK following secondary DMEK in the same eye
: Purpose: To identify causes of reduced visual acuity after Descemet stripping (automated) endothelial keratoplasty (DSEK/DSAEK) and to determine whether such eyes can be successfully ‘repaired’ with a secondary Descemet membrane endothelial keratoplasty (DMEK).Methods: Twelve eyes of 12 patients, who underwent secondary DMEK to manage poor visual outcome after initial DSEK/DSAEK, were evaluated with biomicroscopy, Pentacam imaging, and specular and confocal microscopy, before and at 1, 3 and 6 months after DMEK.Results: Four causes of reduced optical quality of the transplanted host cornea could be identified in DSEK/DSAEK: five eyes (42%) showed large host‐Descemet remnants within the visual axis during surgery; six eyes (50%) irregular graft thickness; six eyes subtle ‘stromal waves’; and nine eyes (75%) high reflectivity at the donor‐to‐host interface. After DMEK graft replacement, all corneas cleared and achieved a best corrected visual acuity of ≥20/25 (≥0.8), except for one with a partial Descemet graft detachment. Pachymetry values decreased from 670 (±112) μm before to 517 (±57) μm after secondary DMEK. Higher‐order aberrations (Coma and Trefoil) at the posterior surface tended to be lower (p = 0.07) in DMEK grafts than in DSEK/DSAEK grafts.Conclusion: Host‐Descemet remnants at the donor‐to‐host interface, interface reflectivity, graft thickness irregularity and donor stromal contraction may contribute to poor visual outcome after DSEK/DSAEK, without causing permanent host corneal damage, as in most cases, complete visual recovery could be achieved by performing a secondary DMEK.
- 6 June 2012
- Published by Wiley in Acta Ophthalmologica
- Vol. 91 (2) , 145-150
Standardized ‘no‐touch’ donor tissue preparation for DALK and DMEK: harvesting undamaged anterior and posterior transplants from the same donor cornea
: Purpose: To describe a standardized ‘no‐touch’ harvesting technique of anterior and Descemet membrane (DM) grafts for use in deep anterior lamellar keratoplasty (DALK) and Descemet membrane endothelial keratoplasty (DMEK), which provides undamaged anterior and posterior corneal grafts.Methods: A retrospective evaluation was performed of our standard method for harvesting DM grafts and DALK grafts (Technique I; n = 31) versus a newly designed ‘no‐touch’ technique (Technique II; n = 31), in which a peripheral ring of trabecular meshwork tissue is left in‐situ, and the DM graft is trephined on an underlying soft contact lens. Endothelial cell density (ECD) before and immediately after DM stripping was used as the main outcome parameter.Results: Endothelial cell density did not differ within Techniques I and II (before versus after DM stripping) (p = 0.75 and p = 0.54, respectively) or among Techniques I and II (p = 0.61). With the latter technique, anterior corneal grafts and posterior DM grafts could be harvested with negligible damage to the endothelial cell layer or the posterior stromal bed. All 93 grafts (62 DM grafts) were eligible for transplantation, and six months post‐operatively all transplants used were functional.Conclusion: The new technique offers the following advantages: (i) production of ‘undamaged’ grafts for DALK and DMEK, (ii) better controlled tissue handling of the thin DM graft during DM stripping and (iii) an increase in availability of corneal grafts obtained from the same donor tissue pool.
- 6 June 2012
- Published by Wiley in Acta Ophthalmologica
- Vol. 91 (2) , 145-150
Standardized ‘no‐touch’ donor tissue preparation for DALK and DMEK: harvesting undamaged anterior and posterior transplants from the same donor cornea
: Purpose: To describe a standardized ‘no‐touch’ harvesting technique of anterior and Descemet membrane (DM) grafts for use in deep anterior lamellar keratoplasty (DALK) and Descemet membrane endothelial keratoplasty (DMEK), which provides undamaged anterior and posterior corneal grafts.Methods: A retrospective evaluation was performed of our standard method for harvesting DM grafts and DALK grafts (Technique I; n = 31) versus a newly designed ‘no‐touch’ technique (Technique II; n = 31), in which a peripheral ring of trabecular meshwork tissue is left in‐situ, and the DM graft is trephined on an underlying soft contact lens. Endothelial cell density (ECD) before and immediately after DM stripping was used as the main outcome parameter.Results: Endothelial cell density did not differ within Techniques I and II (before versus after DM stripping) (p = 0.75 and p = 0.54, respectively) or among Techniques I and II (p = 0.61). With the latter technique, anterior corneal grafts and posterior DM grafts could be harvested with negligible damage to the endothelial cell layer or the posterior stromal bed. All 93 grafts (62 DM grafts) were eligible for transplantation, and six months post‐operatively all transplants used were functional.Conclusion: The new technique offers the following advantages: (i) production of ‘undamaged’ grafts for DALK and DMEK, (ii) better controlled tissue handling of the thin DM graft during DM stripping and (iii) an increase in availability of corneal grafts obtained from the same donor tissue pool.